NCT01658722终止不适用
A Phase 3b Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies ELN15727-301 and 302 But Did Not Enroll in Study ELN115727-351
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 169
- 主要终点
- Dependence Scale
研究概览
简要总结
A Phase 3b, Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies ELN115727-301 and 302 but did not Enroll in Study ELN115727-351.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Observational
Long term follow-up
干预措施: Bapineuzumab (Drug)
结局指标
主要结局
Dependence Scale
时间窗: 4 years
Caregiver's assessment of a patient's need for assistance
次要结局
未报告次要终点
研究者
相似试验
终止
3 期
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease PatientsAlzheimer DiseaseNCT00996918Pfizer198
终止
3 期
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's DiseaseNCT00937352JANSSEN Alzheimer Immunotherapy Research & Development, LLC896
招募中
2 期
Bumetanide in Patients With Alzheimer's DiseaseAlzheimer DiseaseNCT06052163Stanford University40
终止
3 期
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease PatientsAlzheimer DiseaseNCT00667810Pfizer901
终止
3 期
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease PatientsAlzheimer DiseaseNCT00676143Pfizer1,100